By drastically reducing a drug's risk of failure by guiding it to human testing, PharmaStart
expects large drug companies to eye such projects more willingly than they would otherwise.
The
company decided to set up the institute, he adds, because it
expects to get «a
large competitive advantage» if it can efficiently translate genetic information into
drug targets.